Antihypertensive agent

Abstract: An antihypertensive agent containing an effective amount of dipeptide Tyr-Pro and/or a pharmaceutically acceptable salt thereof, the effective amount being from 0.05 to 10mg/kg body weight/day, and a method for producing the same.

Description: The present invention relates to an antihypertensive agent containing as an active ingredient a dipeptide having antihypertensive effect, which agent may be utilized for medicine, foods for specified health use and healthy foods, and which agent exhibit the effect even in a small dose. Angiotensin converting enzyme (ACE), having close relationship with manifestation of hypertension, exists mainly in lungs or angioendothelial cells. ACE is known to exhibit a strong hypertensive effect by cleaving angiotensin I produced by renin, to produce angiotensin II, a bioactive peptide which causes contraction of a smooth muscle of a blood vessel. In addition, ACE degrades and inactivates bradykinin which has antihypertensive effect. Accordingly, ACE has a hypertensive effect, arid it is thus believed that blood pressure may be suppressed by inhibiting the activity of this enzyme. There have been found substances having ACE inhibiting ability among various natural products or synthetic products. Some of such substances have already been put to practical use as an antihypertensive agent. For example, captopril (D-2-methyl-3-mercaptopropanoyl-L-proline) is a well-known synthetic chemical product having ACE inhibiting ability. However, special attention must be paid at all times to safety aspects of these synthetic chemical products. As natural products, it has been reported that various anti ACE peptides are contained in milk protein, soybean protein or fish meat protein. These natural ACE inhibitory substances are proposed for practical use as antihypertensive agents having low toxicity and great safety. However, most of these antihypertensive peptide are contained only in small amount in such natural products and therefore sufficient effect cannot be expected in practical oral intake. In addition, most of the peptides do not have strong antihypertensive effect even if the peptides have strong ACE inhibition activity. Matsuda H et al (Nippon Shokuhin Kogyo Gakkaishi, vol 39, no 8, 1992, pgs 678-683) carried out ACE-I inhibition tests in vitro on various dipeptides including Tyr-Pro, which had an IC 50 of 2440 µM. Recently, a report has been made on two tripeptides having strong ACE inhibiting activity, Val-Pro-Pro and Ile-Pro-Pro, derived from lactic acid bacteria-fermented milk (J. Dairy Sci. 78:777-783). Further, strong antihypertensive effect of these tripeptides has been confirmed in spontaneously hypertensive rats (SHR) (J. Dairy Sci. 78:1253-1257). However, since the tripeptides is produced by proteinase which is produced by lactic acid bacteria as lactic acid fermentation proceeds in milk, the resulting amount of tripeptides tends to vary depending on the conditions of fermentation. It is thus difficult to obtain the tripeptides in a stable amount. It has also been reported that yogurt produced by lactic acid bacteria fermentation of milk as a raw material has antihypertensive effect (Japanese Laid-open Patent Application No.95-123977). However, the active substance for antihypertensive effect has yet been unknown. Therefore, it is desired to provide a natural antihypertensive peptide, which is specified as an active substance, can be produced in an industrially stable manner, is effective in a small dose, and has greater safety. It is an object of the present invention to provide an antihypertensive agent to be used for medicines, foods for specified health use and healthy foods, which is highly safe and is effective in oral dosage. It is another object of the present invention to provide an antihypertensive agent which is effective even in a low oral dosage. According to the present invention, there is provided an antihypertensive agent comprising an effective amount of peptides selected from the group consisting of a dipeptide Tyr-Pro, a pharmaceutically acceptable salt of the dipeptide Tyr-Pro, and mixtures thereof, said effective amount being from 0.05 to 10mg/kg body weight/day. DE 3047596 discloses the use of dipeptide Tyr-Pro as antipsychotic, neuroleptic and tranquilizing agents. The antihypertensive agent of the present invention contains an effective amount of dipeptide Tyr-Pro and/or a salt thereof. The salt may be enumerated by a pharmaceutically acceptable salt, including an inorganic acid salt, such as hydrochlorate, sulfate or phosphate, and an organic acid salt, such as citrate, maleate, fumarate, tartarate or lactate. The antihypertensive agent of the present invention containing the dipeptide Tyr-Pro and/or the salt thereof as an active ingredient may be produced by a method of treating a food material containing a peptide and/or a protein including the amino acid sequence Tyr-Pro with a proteinase, or a publicly known organic synthesis. More preferably, the antihypertensive agent may be produced by culturing lactic acid bacteria, preferably lactic acid bacteria of the genus Lactobacillus , in a medium containing a peptide and/or a protein including the amino acid sequence Tyr-Pro, thereby obtaining a cultured liquid containing the dipeptide Tyr-Pro. That is, the dipeptide Tyr-Pro may be obtained by cultivation treatment of the medium with lactic acid bacteria, preferably lactic acid bacteria of the genus Lactobacillus. The lactic acid bacteria of the genus Lactobacillus may include, for example, Lactobacillus helveticus, Lactobacillus delbruekii subsp. Bulgaricus, and Lactobacillus acidophilus. Of these, Lactobacillus helveticus is particularly preferred. The medium is not particularly limited provided that the medium contains a peptide and/or a protein including amino acid sequence Tyr-Pro, and may include mediums derived from various food materials containing animal milk proteins such as animal whole milk, skim milk, and casein of an animal milk, and food materials containing vegetable proteins such as corn, corn protein, wheat, wheat protein, soybean, delipidized soybean and soybean protein; and commercially available mediums for lactic acid bacteria such as Briggs liver broth and MRS broth. Further, the medium may also be an aqueous solution containing natural food materials containing animal milk proteins and/or vegetable proteins including amino acid sequence Tyr-Pro, to which other mediums for lactic acid bacteria, a yeast extract, vitamins or minerals have optionally been added. The culturing of the lactic acid bacteria may be performed by adding pre-cultured lactic acid bacteria starter to the medium which have been previously heat-sterilized and cooled to the predetermined temperature for incubation. The inoculation-amount of the lactic acid bacteria starter may preferably be 10 5 to 10 7 cells of lactic acid bacteria/ml medium. The temperature for incubation is usually 20 to 50°C and preferably 30 to 45°C. The incubation time is usually 3 to 48 hours and preferably 6 to 24 hours. Particularly, it is preferred to perform cultivation in the medium having pH in a range of 3.5 to 7, more preferably 4 to 5, in order to perform cultivation of lactic acid bacteria efficiently. Further, it is preferred to perform pH-stat cultivation maintaining pH in a range of 4 to 7. The incubation may be terminated, without restriction, when the number of lactic acid bacteria exceeds 10 8 cells/ml. Further, the cultured liquid containing dipeptide Tyr-Pro obtained by the aforementioned method may be centrifuged, and the resulting supernatant may be subjected to purifying treatment with a reverse-phase resin, for obtaining an antihypertensive agent in which the content of the active ingredient, dipeptide Tyr-Pro, is increased. The centrifugation may preferably be performed, for example, at 5,000 to 20,000rpm for 1 to 10 minutes. The centrifugation may also be performed in a centrifugator. The purifying treatment with a reverse-phase resin may be performed by absorption and elution of the dipeptide with a reverse-phase resin, and/or by reverse-phase chromatography, thereby increasing purity of dipeptide Tyr-Pro. The absorption and elution with the reverse-phase resin may be performed by, for example, treating the cultured liquid by a column method or a batch method with a resin such as "Preparative C18" (manufactured by WATERS INC.) as a reverse-phase resin, and then eluting the absorbed fraction with a polar solvent such as water, methanol, ethanol, 1-propanol, 2-propanol or acetonitrile, preferably an aqueous solution containing 20 v/v% of acetonitrile, followed by evaporation of the solvent, for concentrating dipeptide Tyr-Pro. The treatment by reverse-phase chromatography may be performed, without limitation, by publicly known reverse-phase high performance liquid chromatography (HPLC). HPLC may be performed by a linear gradient method using similar solvents to those enumerated in the absorption and elution with the reverse-phase resin, for obtaining dipeptide Tyr-Pro with high purity. The treatment by reverse-phase chromatography may be repeated plural times for further increasing the purity of the dipeptide Tyr-Pro. The antihypertensive agent obtained is usually a mixture of peptides, and may contain other peptides than dipeptide Tyr-Pro. For use as foods and drinks, the cultured liquid containing the dipeptide Tyr-Pro and/or purified products thereof may be used directly. Alternatively, the agent may be powdered by freeze drying, spray drying or drum dryer drying, before use. The effective amount of the antihypertensive agent of the present invention varies depending upon the age and condition of a patient, and is in a range of 0.05 to 10mg/kg body weight/day. It is preferable to administer 0.3 to 3.0mg/kg body weight/day. If the dose is not less than 0.05mg/kg body weight/day, sufficient effect may be expected. If the dose is not more than 10mg/kg body weight/day, the effect may be exhibited efficiently. The dipeptide Tyr-Pro was orally administered to WKY rats showing normal blood pressure (18 weeks old, body weight of 320g, n=5) in an amount of 10mg/kg body weight/day continuously for one month, and no abnormality was found in behavior, appearance, blood pressure and autopsy of the rats. Foods fermented with Lactobacillus bacteria have been eaten by human beings for a long time, and it is therefore assumed that Tyr-Pro contained in the antihypertensive agent of the present invention has no problem in safety. Since the antihypertensive agent of the present invention contains dipeptide Tyr-Pro as an active ingredient, it can reduce blood pressure in significantly low dose, compared with antihypertensive peptides derived from food materials reported to date. In addition, the antihypertensive agent of the present invention is highly safe, and thus can be used as medicine, foods for specified health use and healthy foods. Since producing Tyr-Pro invention includes culturing of lactic acid bacteria in a medium containing a peptide and/or a protein, the antihypertensive agent containing as an active ingredient dipeptide Tyr-Pro having great safety may be produced easily at low cost from a material such as natural peptides and proteins. The present invention will be explained in further detail with reference to Examples which are given only for illustration and are not intended for limiting the invention. Preparation Example 1 10 kg of a 9 wt% aqueous solution of skim milk powders were inoculated with 300 g of fermented milk fermented with Lactobacillus helveticus CPN4 (FERM BP-4835) as a lactic acid bacteria starter. The inoculated solution was incubated at 37°C for 8 hours. When curd was formed and the pH reached 4.2, the incubation was terminated and the solution was cooled. In the obtained fermented milk solution, 1.0mg/100g of dipeptide Tyr-Pro was contained. 10kg of the obtained fermented milk solution were centrifuged at 10,000rpm for 10 minutes, to retrieve 8.4 kg of whey. In the whey, 1.1mg/100g of dipeptide Tyr-Pro were contained. L. helveticus CPN4 strain belongs to L. helveticus, and was deposited at National Institute of Bioscience and Human-Technology Agency of Industrial Science and Technology on October 17, 1994, and has been accorded accession number FERM BP-4835. FERM BP-4835 has been accepted for deposit under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. All restrictions on the availability to the public of FERM BP-4835 will be irrevocably removed upon the granting of a patent. Example 1 120mg of the whey obtained in Preparation Example 1 were subjected to an absorption treatment through 10 sep-pak cartridges (WATERS INC.), and subsequently to an elution treatment under various conditions shown in Table 1 with an acetonitrile containing 0.1wt% of TFA (trifluoroacetic acid) (solution B) diluted with an aqueous solution containing 0.1wt% of TFA (solution A). A sample eluted without absorption and samples eluted under each condition were defined as Fractions 1 to 6, respectively. Each fraction was freeze-dried and dissolved in 40ml of physiological saline to prepare Samples 1 to 6. The obtained whey before fractionation and Samples 1 to 6 were administered to spontaneously hypertensive rats (SHR: from CHARLES RIVER JAPAN INC., five rats per group, 20 to 22 weeks old, male) with a stomach sonde in an amount of lml/animal. The change in the maximal blood pressure after six hours was compared with that of a control group to which physiological saline was administered. The measurement of blood pressure was performed by tail cuff method using a noninvasive blood pressure measurement apparatus (trade name "PE 300", NARKO BIO-SYSTEMS, CO.,LTD.). As a result, a significant antihypertensive effect was observed in Sample 2 as shown in Table 1. Therefore, Fraction 2 was found to be active. Sample Ratio of Solution B (%) Blood Pressure Reduction After 6 hours (Δ SBP±SE) Before Fractionation - -29.6±9.5 Fraction 1 not absorbed -9.6±5.7 Fraction 2 0-10 -22.3±3.2 (Active Fraction) Fraction 3 10-15 -8.1±2.6 Fraction 4 15-20 1.0±6.3 Fraction 5 20-30 -8.8±8.5 Fraction 6 30-50 -7.6±5.3 Control 1.9±8.1 (physiological saline) Subsequently, Sample 2 was subjected to an elution treatment by reverse-phase high performance liqud chromatography (HPLC) under the following conditions according to the elution time shown in Table 2, to further fractionate Sample 2 into four Fractions 2-1 to 2-4. Application amount of Sample 2 in one elution was lml, and elution was repeated 15 times. That is, a total of 15ml of Sample 2 was fractionated. Pump, L6200 INTELLIGENT pump manufactured by HITACHI LTD.; Detector, L4000 UV detector manufactured by HITACHI LTD.; Column, WATERS MICROBONDASPHERE 5µC18 manufactured by NIHON MILLIPORE LTD., Tokyo, Japan; Eluent, Solution A (0.1 wt% aqueous solution of trifluoroacetic acid (TFA)); and Solution B (acetonitrile containing 0.1 wt% of TFA); Gradient, linear gradient from Solution B 0% (Solution A 100%) to Solution B 40% (Solution A 60%) (0 to 60 minutes) Flow rate, 1ml/min. Fractions 2-1 to 2-4 were freeze-dried, and dissolved in 15ml of physiological saline to prepare Samples 2-1 to 2-4. These samples were orally administered to SHR with a stomach sonde in an amount of 1ml/animal, and the change in the maximal blood pressure after six hours was compared with that of a control group to which physiological saline was administered, in the same manner as the above, in order to examine antihypertensive effect. As a result, a significant antihypertensive effect was observed in Fraction 2-2 as shown in Table 2. Therefore, Fraction 2-2 was found to be an active fraction. Sample Elution Time (min) Blood Pressure Reduction After 6 hours (Δ SBP±SE) Fraction 2-1 10.5-16 -13.0±2.8 Fraction 2-2 16-19 -35.0±9.7 (Active Fraction) Fraction 2-3 19-23 -2.8±5.3 Fraction 2-4 23-29 -3.6±5.6 Control (physiological saline) 2.6±6.0 1ml of Sample 2-2 was subjected to elution treatment by the HPLC under the same conditions as those of the above except following the under-mentioned conditions: Gradient, linear gradient from Solution B 5% (Solution A 95%) to Solution B 20% (Solution A 80%) (0 to 60 minutes) This elution was repeated ten times, that is, 10ml in total of Sample 2-2 was subjected to the elution. Each of the obtained Fractions 2-2-1 to 2-2-5 was freeze-dried and dissolved in 10ml of physiological saline to prepare Samples 2-2-1 to 2-2-5. These samples were orally administered to SHR with a stomach sonde in an amount of 1ml/animal, and the change in the maximal blood pressure after six hours was compared with that of a control group to which physiological saline was administered, in the same manner as the above, in order to examine antihypertensive effect. As a result, a significant antihypertensive effect was observed in Fraction 2-2-2 as shown in Table 3. Sample Elution Time (min) Blood Pressure Reduction After 6 hours (Δ SBP±SE) Fraction 2-2-1 21.8 -6.6±5.5 Fraction 2-2-2 22.7 -23.0±6.2 (Active Fraction) Fraction 2-2-3 24.0 -9.0±6.5 Fraction 2-2-4 25.2 -6.2±6.2 Fraction 2-2-5 25.8 -3.5±4.8 Control 2.6±6.0 (physiological saline) 1ml of Sample 2-2-2 was subjected to the elution treatment by the HPLC under the same conditions as those for treating Sample 2-2 for purifying the sample, and the amino acid sequence thereof from N-terminus was analyzed with "Automatic Protein Sequencer PPSQ-10 SYSTEM" manufactured by SHIMADZU CO. As a result, it was confirmed that amino acid sequence Tyr-Pro was contained. Alternatively, the purified peptide was hydrolyzed with 6N hydrochloric acid at the temperature of 105°C for 24 hours, and amino acid analysis was performed with high-speed amino acid analysis system (trade name "Amino Acid Analysis System" manufactured by NIHON BUNKOU KOUGYO Co.). As a result, it was confirmed that amino acids Tyr and Pro were contained in equal moles. It was therefore concluded that the obtained peptide was a dipeptide having the sequence Tyr-Pro. Preparation Example 2 100kg of a 9 wt% aqueous solution of skim milk powders were inoculated with 3kg of fermented milk fermented with L. helveticus CPN4 (FERM BP-4835), and cultured at 37°C for 20 hours . The fermented milk solution thus obtained was treated in a Sharpless centrifugal separator at 10,000rpm, to retrieve 78kg of whey. Subsequently, the whey was applied to Preparative C18 packed column (3 litter capacity, manufactured by WATERS INC.). The column was then washed with 10kg of a 5% aqueous solution of acetonitrile, followed by an elution treatment with 5kg of a 10% aqueous solution of acetonitrile. The eluted fraction gave 1186mg of freeze-dried product. This freeze-dried product contained 652mg of dipeptide Tyr-Pro. The purity of the dipeptide Tyr-Pro was 55%. Example 2 Antihypertensive effect of the fermented milk solution obtained in Preparation Example 1 was examined. Measurement of antihypertensive effect was performed utilizing SHR according to the method of Example 1. 4ml/animal (12ml/kg body weight) of the fermented milk solution or an unfermented milk solution was orally administered to SHR, and maximal blood pressure after six hours was measured. As a result, antihypertensive effect was confirmed. The results are shown in Table 4. Sample Blood Pressure Reduction After 6 hours (Δ SBP±SE) Unfermented Milk Solution -3.5±4.2 CPN4 Fermented Milk Solution -20.3±5.2 Example 3 The antihypertensive peptide Tyr-Pro identified in Example 1 was solid-phase synthesized with an automatic peptide synthesizer PPSM-8 manufactured by SHIMADZU CO. The elution time of the obtained peptide Tyr-Pro on HPLC was the same as that of the peptide purified in Example 1. Antihypertensive effect of the synthesized peptide was confirmed by the following method. 0.05, 0.1, 0.3, 1.0, 3.0 or 10mg/kg body weight of the synthesized peptide Tyr-Pro was orally administered to SHR, and the maximal blood pressure after six hours was measured and compared with that of a control group to which physiological saline was administered, in the same manner as in Example 1. The results are shown in Table 5. From the results in Table 5, dose-dependent effect in a range of 0.05 to 3.0mg/kg body weight was confirmed. Amount of Tyr-Pro (mg/kg) Blood Pressure Reduction After 6 hours (Δ SBP±SE) 10 -32.1±7.4 3 -30.5±6.7 1 -27.4±7.1 0.3 -20.8±4.1 0.1 -10.2±4.0 0.05 -8.1±3.3 Control (physiological saline) -3.6±2.1

Claims: Use of peptides selected from the group consisting of a dipeptide Tyr-Pro, a pharmaceutically acceptable salt of the dipeptide Tyr-Pro, and mixtures thereof in the manufacture of an antihypertensive agent, wherein said peptides are to be used in the amount of 0.05 to 10mg/kg body weight/day. Use of claim 1 wherein said pharmaceutically acceptable salt is selected from the group consisting of hydrochloride, sulfate, phosphate, citrate, maleate, fumarate, tartarate, lactate and mixtures thereof. Use of claim 1 wherein said peptides are to be used in the amount of 0.3 to 3.0mg/k body weight/day. Use of claim 1 wherein said agent is in an oral dosage form.

Inventors: YAMAMOTO NAOYUKI, YAMAMOTO, NAOYUKI
Applicants: CALPIS CO LTD, CALPIS CO., LTD.
Application year: 1997
Main classification: A61P9
IPC codes: A61P9, A61K38, A23L1, A61K35, C12P21, C12R1, C07K5